Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Bioatla Inc

BCAB ✓ COMPLIANT ☆ Track — members

Nasdaq · Healthcare · Biotechnology & Medical Research ·

USA Micro Cap Analyst: STRONG BUY

Last Close

$3.09

▼ -10.43%

Market Cap $5.15M · Vol 17.35K

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$5.15M

Micro Cap

Div Yield

N/A

EPS Growth

+8.91%

YoY

RSI (14)

39.94

Momentum

Beta

0.75

vs Market

52W High

$71.50

95.68% below

52W Low

$3.00

3.00% above

Volume

17.35K

Avg 9.40K

P/B

N/A

Price-to-book

ROE

N/A

Return on equity

Free Float

93.94%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Bioatla Inc (BCAB) stock is Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does BCAB pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

-10.69%

-23.89%

-29.29%

-58.80%

YTD

-89.11%

-83.03%

-97.74%

-99.85%

Financials & Valuation

TTM · Annual

Total Revenue	$2.00M
Net Income	$-59,607,000.00
Revenue Growth (YoY)	N/A
Gross Margin	100.00%
Operating Margin	-2,935.25%
Net Profit Margin	-2,980.35%
ROE	N/A
ROA · ROIC	-179.95% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	16.70
P/B	N/A
P/FCF	N/A
EPS Growth	+8.91%
Outstanding Shares	1.67M

Technical Indicators

50-Day SMA	$3.63
200-Day SMA	$14.34
RSI (14)	39.94
Beta	0.75
52-Week High	$71.50
52-Week Low	$3.00

Volume Today	17.35K
Avg Daily Volume (30D)	9.40K
Relative Volume	1.85x
Volatility (10D)	62.89
Volatility (30D)	86.31
Free Float	93.94%

Analyst Consensus

STRONG BUY

Current Price $3.09

Mean Target N/A

52W Low$3.00 52W High$71.50

Current

Target

$3.00 $71.50

Current Analyst target

· 1 analysts

Identifiers

ExchangeNasdaq

FIGIBBG00Y6GBV39

ISINUS09077B2034

CountryUnited States of America

Sub-IndustryBio Therapeutic Drugs

Earnings DateNov 10, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

2359.HK WuXi AppTec Co Ltd -2.85% ARGX.BR argenx SE -3.21% ARGX argenx SE -0.66% INSM Insmed Inc -2.05% 2269.HK WuXi Biologics (Cayman) Inc -1.27%

Company Profile

BioAtla, Inc. is a clinical-stage biopharmaceutical company focused on developing antibody-based therapeutics for the treatment of solid tumor cancer. The Company’s product candidates include Mecbotamab vedotin (BA3011), Ozuriftabmab vedotin (BA3021), evalstotug (BA3071), and BA3182. Its lead product candidate, BA3011, is a conditionally active biologics (CAB) antibody-drug conjugate that targets AXL, which is a protein kinase receptor. The BA3071 is a potential therapeutic for multiple solid tumor types, including soft tissue and bone sarcoma, and non-small cell lung cancer. BA3021 is developing a CAB antibody drug conjugate directed against a receptor tyrosine kinase such as orphan receptor 2 (ROR2). BA3071 is a CAB anti-CTLA-4 antibody that is being developed as a therapeutic for multiple solid tumor indications. BA3182 is designed with an EpCAM binding domain and a CD3 binding domain, both binding domains with CAB activity (Dual-CAB), for the treatment of advanced adenocarcinoma.